IN2014MN01706A - - Google Patents

Info

Publication number
IN2014MN01706A
IN2014MN01706A IN1706MUN2014A IN2014MN01706A IN 2014MN01706 A IN2014MN01706 A IN 2014MN01706A IN 1706MUN2014 A IN1706MUN2014 A IN 1706MUN2014A IN 2014MN01706 A IN2014MN01706 A IN 2014MN01706A
Authority
IN
India
Prior art keywords
bitter taste
active ingredient
fast dissolving
film composition
dissolving film
Prior art date
Application number
Inventor
Hyun Jun Jeong
Ik Hyeon Chang
Dal Geun Kim
Jin Hoo Lee
Jin Hee Um
Hyun Soo Kim
Kyung Tae Jung
Kyu Jeong Yeon
Jin Gyu Park
Original Assignee
Seoul Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120020316A external-priority patent/KR101328350B1/en
Priority claimed from KR1020120117233A external-priority patent/KR101440808B1/en
Application filed by Seoul Pharma Co Ltd filed Critical Seoul Pharma Co Ltd
Publication of IN2014MN01706A publication Critical patent/IN2014MN01706A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Provided is a fast dissolving film composition comprising a medically active component as an active ingredient in which the bitter taste of the active ingredient is masked and the fast dissolving film composition has a high content of 50% or higher. More particularly provided is a pharmaceutical composition which comprises sildenafil or pharmaceutically acceptable salts thereof as an active ingredient and which comprises a combination of a specific bitter taste masking agent to achieve masking of a bitter taste. Further provided is a fast dissolving film composition which comprises a combination of a specific plasticizer to mask a bitter taste and in which the physical properties of the high content film are excellent.
IN1706MUN2014 2012-02-28 2013-02-28 IN2014MN01706A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020120020316A KR101328350B1 (en) 2012-02-28 2012-02-28 Taste masked pharmaceutical composition comprising sildenafil or pharmaceutically acceptable salts thereof as an active ingredient
KR1020120117233A KR101440808B1 (en) 2012-10-22 2012-10-22 Fast dissolving film comprising high dose of sildenafil or pharmaceutically acceptable salts thereof
PCT/KR2013/001679 WO2013129889A2 (en) 2012-02-28 2013-02-28 High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient

Publications (1)

Publication Number Publication Date
IN2014MN01706A true IN2014MN01706A (en) 2015-05-29

Family

ID=49083410

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1706MUN2014 IN2014MN01706A (en) 2012-02-28 2013-02-28

Country Status (7)

Country Link
US (1) US10092651B2 (en)
EP (1) EP2821066B1 (en)
JP (1) JP5941558B2 (en)
CN (1) CN104168895B (en)
CA (1) CA2864322C (en)
IN (1) IN2014MN01706A (en)
WO (1) WO2013129889A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TH121482A (en) 2009-08-19 2013-02-28 นางสาวปัณณพัฒน์ เหลืองธาตุทอง Quinoline derivative-containing pharmaceutical composition
CN103989661B (en) * 2014-05-26 2016-04-20 苏州大学 Sldenafil oral instant membrane and preparation method thereof
KR101538985B1 (en) * 2014-09-02 2015-07-24 주식회사 서울제약 Tadalafil Orally Disintegrating Film and Precess For Producing thereof
CN106999601A (en) * 2014-12-09 2017-08-01 莫诺索尔克斯有限公司 Film product based on straight-chain polysaccharide
CN104586820B (en) * 2015-01-13 2021-04-09 齐鲁制药有限公司 Oral instant film composition of sildenafil with high drug loading
CN104546807B (en) * 2015-01-21 2020-09-01 齐鲁制药有限公司 Olanzapine oral instant film agent
LT3263106T (en) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. METHOD OF REDUCING BITTERNESS OF QUINOLINE DERIVATIVES
CA2994925C (en) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
EP3463317A4 (en) * 2016-06-07 2020-01-08 Aridis Pharmaceuticals, Inc. METHOD FOR THE PRODUCTION OF QUICK-DISOLDERING THIN FILMS WITH BIOACTIVE MATERIAL AND IMPROVED THERMAL STABILITY
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CN110505871B (en) * 2017-03-13 2023-08-15 纳米及先进材料研发院有限公司 Highly loaded rapidly disintegrating membranes for drug absorption
CN106860404A (en) * 2017-04-13 2017-06-20 中国药科大学 A kind of sildenafil citrate taste masking resin complexes and its application
BR112019023064A2 (en) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd treatment of hepatocellular carcinoma
CN109717282A (en) * 2017-10-30 2019-05-07 上海冠生园食品有限公司 A kind of candy and preparation method thereof rich in anthocyanidin
US20210007977A1 (en) * 2018-02-19 2021-01-14 Monell Chemical Senses Center Compositions and methods of ameliorating pharmaceutical aversiveness with salts
CN109010324B (en) * 2018-08-30 2021-07-02 南京康川济医药科技有限公司 Sildenafil oral dissolving film agent and preparation method thereof
CN111466564A (en) * 2019-01-24 2020-07-31 甄崇礼 Oral instant film containing natural active polysaccharide and preparation method thereof
CN110128429A (en) * 2019-04-30 2019-08-16 孙常全 A kind of silaenafil-acesulfame potassium salt form and its preparation method and application
JP7817737B2 (en) * 2019-09-04 2026-02-19 シーズンズ バイオテクノロジー （タイジョウ） カンパニー リミテッド Coated granules, solid dispersions and formulations containing vortioxetine hydrobromide for oral taste masking
US11179331B1 (en) 2020-04-21 2021-11-23 Cure Pharmaceutcai Holding Corp Oral soluble film containing sildenafil citrate
GR20200100430A (en) * 2020-06-01 2022-01-13 Κυριακος Ηλια Κυπραιος Rapidly dissolving oral strips for per os administration of drugs and other bioactive compounds to humans
MX2023007464A (en) * 2020-12-22 2023-08-30 Solugen Inc Bitter masking agent.
CN115252587A (en) * 2022-08-19 2022-11-01 南京泛太化工医药研究所 Oral instant film and preparation method thereof
CN116270553B (en) * 2023-02-01 2024-05-07 北京悦康科创医药科技股份有限公司 A kind of edenafil orodispersible film and preparation method thereof
KR20250177169A (en) * 2024-06-14 2025-12-23 한미약품 주식회사 Orally disintegrating tablet comprising pregabalin or its pharmaceutically acceptable salt thereof
CN119280194B (en) * 2024-09-06 2025-10-28 广州朗圣药业有限公司 Sildenafil oral film-dissolving agent, and preparation method and application thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US652024A (en) 1898-12-08 1900-06-19 James Gray Valve mechanism for automatic water-heaters.
TW271400B (en) * 1992-07-30 1996-03-01 Pfizer
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
NZ504436A (en) 1997-11-12 2001-08-31 Bayer Ag 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
KR100353014B1 (en) 1998-11-11 2002-09-18 동아제약 주식회사 Pyrazolopyrimidinone derivatives for the treatment of impotence
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
EP1301186A1 (en) * 2000-07-19 2003-04-16 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
DE10207394B4 (en) 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Taste-masked oblate medicinal preparation
GB0219516D0 (en) * 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil
KR20060031552A (en) 2004-10-08 2006-04-12 박영국 Deep Sea Water Intake Method Using Water Inlet Line
US20070092553A1 (en) * 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
RU2437657C2 (en) * 2006-03-16 2011-12-27 Новартис Аг Hard drug form containing active agent with disguised taste
KR101304343B1 (en) 2006-04-06 2013-09-11 한미사이언스 주식회사 Fast dissolving oral formulation of pde-5 inhibitors
CN105168186A (en) 2006-10-02 2015-12-23 Apr应用制药研究股份公司 Non-mucoadhesive film dosage forms
JP2010515761A (en) 2007-01-12 2010-05-13 モノソル アールエックス リミテッド ライアビリティ カンパニー High dose film composition and process for its production
US20080220029A1 (en) 2007-03-05 2008-09-11 Charlene Ng Fast-dissolving/disintegrating film preparation having high proportion of active
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
US20100297232A1 (en) 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
KR101074271B1 (en) 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 Fast dissolving oral dosage form containing steviosides as a taste masking agent
DE102010049708A1 (en) * 2010-10-28 2012-05-03 Hexal Ag Oral pharmaceutical film formulation for bitter-tasting drugs
CA2827069C (en) 2011-02-11 2021-02-16 Ctc Bio, Inc. Sildenafil-free base-containing film preparation and method for producing same
KR101188594B1 (en) * 2011-12-06 2012-10-08 (주)씨엘팜 Bitter taste masked oral thin film formulation of sildenafil citrate

Also Published As

Publication number Publication date
CN104168895A (en) 2014-11-26
EP2821066A2 (en) 2015-01-07
JP5941558B2 (en) 2016-06-29
WO2013129889A3 (en) 2013-10-24
JP2015504916A (en) 2015-02-16
EP2821066B1 (en) 2018-04-25
WO2013129889A9 (en) 2014-10-16
WO2013129889A2 (en) 2013-09-06
US20150025084A1 (en) 2015-01-22
CA2864322A1 (en) 2013-09-06
US10092651B2 (en) 2018-10-09
CA2864322C (en) 2016-08-09
CN104168895B (en) 2020-02-21
EP2821066A4 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
IN2014MN01706A (en)
MX391180B (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
MX2019007956A (en) SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT.
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
IN2014MN01755A (en)
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
MX2015010971A (en) Novel pyrazole derivative.
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
IN2013MU03583A (en)
MY180145A (en) Cenicriviroc compositions and methods of making and using the same
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
EP3162804A8 (en) New benzodiazepine derivative and use thereof
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
HK1214519A1 (en) Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof
MX2023012198A (en) Amantadine compositions, preparations thereof, and methods of use.
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
HK1221412A1 (en) Vesicles
WO2014007549A3 (en) Composition for preventing or treating colitis comprising s-allyl-l-cysteine as active ingredient, and medical preparation comprising same
GEP20196957B (en) Crystalline forms of s-acetyl glutathione, their reparations and uses in pharmaceutical and nutraceutical formulations
IN2014DN10134A (en)